Leslie Popplewell, MD
Hematology · Duarte, CANPI 1457310450
Payments from drug & device makers
Across 171 payments — averaging $11,546 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$715K
- Janssen Research & Development, LLC$515K
- Novartis$294K
- Genentech, Inc.$207K
- Gilead$118K
- Amgen$37K
- plus $88K from 17 others
Across 11 payments — averaging $4911.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Celltrion, Inc.$41K
- Novartis$11K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$46,84781%
- Speaking & faculty fees$6,44411%
- Travel & lodging$2,3784%
- Food & beverage$2,0163%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $714,879 |
| Janssen Research & Development, LLC | 40 | $514,800 |
| Novartis | 23 | $293,840 |
| Genentech, Inc. | 18 | $206,659 |
| Gilead(2 entities) | 16 | $118,468 |
| Amgen | 8 | $37,320 |
| Pfizer | 8 | $37,246 |
| Acerta Pharma LLC | 1 | $20,643 |
| ADC Therapeutics America, Inc. | 4 | $12,322 |
| Acrotech Biopharma Inc. | 5 | $8,174 |
| Seagen Inc. | 6 | $7,103 |
| Novartis Pharma AG | 2 | $1,811 |
| F. Hoffmann-la Roche AG | 1 | $319 |
| Bristol Myers Squibb | 2 | $185 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Legend Biotech USA Inc. | 2 | $117 |
| Kyowa Kirin, Inc. | 1 | $108 |
| Pharmaessentia USA Corporation | 2 | $59 |
| Johnson & Johnson | 2 | $42 |
| Sanofi | 1 | $28 |
| Beigene USA, Inc. | 1 | $28 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,974,317 in reported general payments places this provider in the 75th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 52 | $671,513 |
| BrukinsaZanubrutinib | 26 | $379,805 |
| CalquenceAcalabrutinib Maleate | 13 | $200,267 |
| GleevecImatinib Mesylate | 14 | $147,495 |
| EliquisApixaban | 32 | $20,854 |
| Atovaquone | 12 | $6,001 |
| Acyclovir | 76 | $796 |
| Potassium Chloride | 11 | $267 |
| Dexamethasone | 17 | $216 |
| Allopurinol | 25 | $106 |
| Pantoprazole Sodium | 13 | $93 |
| Amitriptyline Hcl | 11 | $78 |
| Levetiracetam | 11 | $69 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 29 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $28 | $379,80526 claims |
| NovartisGleevec | $293,840 | $147,49514 claims |
| PfizerEliquis | $37,246 | $20,85432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 178 hematology providers in California.
Other hematology in Duarte
- Alex HerreraDuarte$50.9M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
- Vinod PullarkatDuarte$10M
- Ibrahim AldossDuarte$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.